In our previous work in a xenograft model of leukemia, we compared two T cell manufacturing methods that are commonly used in adoptive immunotherapy clinical trials, CD3/CD28 Dynabead and OKT3/IL-2. This evidence concerns the gene IL2 and leukemia.